Edition:
United States

AbbVie Inc (ABBV.PH)

ABBV.PH on Philadelphia Stock Exchange

65.92USD
2:59pm EDT
Change (% chg)

$-0.45 (-0.68%)
Prev Close
$66.37
Open
$66.33
Day's High
$66.41
Day's Low
$65.86
Volume
21,331
Avg. Vol
32,276
52-wk High
$68.12
52-wk Low
$55.15

ABBV.PH

Chart for ABBV.PH

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $105,551.00
Shares Outstanding(Mil.): 1,591.54
Dividend: 0.64
Yield (%): 3.86

Financials

  ABBV.PH Industry Sector
P/E (TTM): 17.07 14.31 17.43
EPS (TTM): 3.88 -- --
ROI: 12.64 -7.26 -5.41
ROE: 130.90 -6.76 -4.69

Wall Street tumbles as reform hopes fade with Trump crisis

The S&P 500 and the Dow notched their biggest one-day fall since Sept. 9 as investor hopes for tax cuts and other pro-business policies faded after reports that U.S. President Donald Trump tried to interfere with a federal investigation set off alarm bells on Wall Street. | Video

May 17 2017

BRIEF-Alembic Pharma gets FDA nod for generic version of Abbvie's Trilipix

* Says received U.S. Food & drug administration (FDA) approval for fenofibric acid delayed-release capsules Source text for Eikon: Further company coverage:

May 14 2017

AbbVie profit beats on Humira demand; cheers Trump tax plan

AbbVie Inc reported a bigger-than-expected quarterly profit, lifted by demand for its flagship drug, Humira, and called President Donald Trump's tax plan "encouraging".

Apr 27 2017

UPDATE 3- AbbVie profit beats on Humira demand; cheers Trump tax plan

* Shares rise as much as 3.8 pct (Adds conference call details, analyst comments; updates shares)

Apr 27 2017

BRIEF-Abbvie Q1 adjusted earnings per share $1.28

* Reaffirms fy 2017 gaap earnings per share view $4.55 to $4.65

Apr 27 2017

Drugmaker AbbVie's profit rises 26.4 pct

April 27 AbbVie Inc reported a 26.4 percent jump in quarterly profit on Thursday, helped by higher demand for its top-selling treatment, Humira.

Apr 27 2017

BRIEF-Aquinnah receives $10 mln investment from Pfizer, Abbvie

* Aquinnah Pharmaceuticals receives $10 million investment from Pfizer and Abbvie to research breakthrough approach to neurodegenerative disease

Apr 25 2017

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

Apr 21 2017

AbbVie cancer drug fails two late-stage trials

AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

Apr 19 2017

UPDATE 1-AbbVie cancer drug fails two late-stage trials

April 19 AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

Apr 19 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.92 -0.61
Pfizer Inc. (PFE.N) $32.14 -0.02
Novartis AG (NOVN.S) CHF78.60 -0.50
Merck & Co., Inc. (MRK.N) $64.92 -0.12
Roche Holding Ltd. (ROG.S) CHF266.60 -0.60
Roche Holding Ltd. (RO.S) CHF267.75 +0.25
Abbott Laboratories (ABT.N) $44.71 +0.76
Eli Lilly and Co (LLY.N) $78.05 -0.29
Sanofi SA (SASY.PA) €87.74 +0.43

Earnings vs. Estimates